Active substance Daclatasvir
US Brand Generic Daclinza
IN Brand Natdac | Dacihep | MyDacla | Daclahep
Manufacturing by Natco | Zydus | Mylan | Hetero
Strength 30mg / 60mg
Form release bottle 28 tabs
Estimated shipping time 7 – 18 days (Depending from the Country)
Availability, Prices & Order through request form

DescriptionDosageSide EffectsPhotos

Daclatasvir is used along with another medication sofosbuvir to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body. It is not known if daclatasvir prevents the spread of hepatitis C to other people.

How should this medicine be used?

Daclatasvir comes as a tablet to take by mouth. It is usually taken with or without food once a day. Daclatasvir must be taken in combination with sofosbuvir, usually for 12 weeks. Take daclatasvir at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take daclatasvir exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Continue to take daclatasvir even if you feel well. Do not stop taking daclatasvir or sofosbuvir without talking to your doctor.

60 mg orally once a day for 12 weeks

Comments:
-Sustained virologic response rates reduced in HCV genotype 3-infected patients with cirrhosis using this drug with sofosbuvir for 12 weeks; optimal duration of therapy has not been established for patients with cirrhosis.
-The manufacturer product information for sofosbuvir should be consulted.

Use: In combination with sofosbuvir, for the treatment of patients with chronic HCV genotype 3 infection

No adjustment recommended.

Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): No adjustment recommended.
Decompensated cirrhosis: Data not available

Coadministration with strong CYP450 3A inhibitors: Dose should be reduced to 30 mg orally once a day.
Coadministration with moderate CYP450 3A inducers: Dose should be increased to 90 mg orally once a day.
Coadministration with strong CYP450 3A inducers: Contraindicated

The dose of this drug should not be reduced for side effects.

If sofosbuvir is permanently discontinued, this drug should also be discontinued.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Any degree of renal dysfunction: No adjustment recommended.

Comments: This drug is highly protein-bound; significant removal via dialysis is not likely.

  1. headache
  2. diarrhea
  1. near fainting or fainting
  2. dizziness or lightheadedness
  3. weakness or not feeling well
  4. shortness of breath
  5. chest pain
  6. memory problems
  7. confusion